key: cord-270528-3rsv3jlh
authors: Yazdanpanah, Fereshteh; Hamblin, Michael R.; Rezaei, Nima
title: The immune system and COVID-19: Friend or foe?
date: 2020-06-02
journal: Life Sci
DOI: 10.1016/j.lfs.2020.117900
sha: 
doc_id: 270528
cord_uid: 3rsv3jlh

AIM: Coronavirus disease 2019 (COVID-19) is a novel highly contagious infection caused by SARS-CoV-2, which has been became a global public health challenge. The pathogenesis of this virus is not yet clearly understood, but there is evidence of a hyper-inflammatory immune response in critically ill patients, which leads to acute respiratory distress syndrome (ARDS) and multi-organ failure. MATERIAL AND METHODS: A literature review was performed to identify relevant articles on COVID-19 published up to April 30, 2020. The search resulted in 361 total articles. After reviewing the titles and abstracts for inclusion, some irrelevant papers were excluded. Additional relevant articles were identified from a review of citations referenced. KEY FINDINGS: SARS-CoV-2, directly and indirectly, affects the immune system and avoids being eliminated in early stages. On the other hand, the secretion of inflammatory cytokines creates critical conditions that lead to multi-organ failure. SIGNIFICANCE: The immune system which is affected by the virus tries to respond via a cytokine storm and hyperinflammation, which itself leads to further multi-organ damage and even death.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the coronavirus disease 2019 (COVID- 19) , and has affected people's lives globally, since first observed in Wuhan, China in the last days of 2019 (1, 2) . The main route of virus entry and transmission is respiratory droplets that are expelled and absorbed by the mucous membranes, especially the nasal and larynx mucosa. COVID-19 spreads readily via person-to-person contact (3) . The clinical spectrum of COVID-19 varies from an asymptomatic form to severe respiratory failure (SRF) that necessitates mechanical ventilation and support in an intensive care unit (ICU) and can lead to multi-organ failure. Pneumonia is the most frequent serious manifestation of COVID-19, characterized primarily by fever, dry cough, and dyspnea. Other less common symptoms are headaches, sore throat, and rhinorrhea. In addition to respiratory symptoms, gastrointestinal symptoms, myalgia, skin rashes, and neurological involvement have also been reported (1, 3-6).

SARS-CoV-2 belongs to the coronavirus family, members of which have caused two previous epidemics at the beginning of the 21st century; one named SARS-CoV and the other Middle East Respiratory Syndrome (MERS). Coronaviruses are large enveloped viruses with a positive sense RNA genome. The lipid bilayer envelope of the virus contains several proteins with different tasks. The spike or S glycoprotein, has two domains of S1 and S2, is responsible for invasion, attachment, and entry into human cells. The receptor-binding domain (RBD) in S1 interacts with angiotensin-converting enzyme 2 (ACE2) on the human host cell surface, which is J o u r n a l P r e -p r o o f 4 a similar entry mechanism to SARS-CoV; however, the S2 domain is responsible for virus-cell membrane fusion and viral entry with higher affinity (7) . Higher expression of the ACE2 receptor in adults compared to children may be a reason for the higher infection rate seen in adults (8, 9) . Another noteworthy point is the increased level of enzymes in the liver, heart, and kidneys in COVID-19 patients with pneumonia, which is consistent with the tissue expression profile of the ACE2 receptor (10) ; this could also explain the occurrence of multi-organ failure in some patients (11).

Since both SARS-CoV and SARS-CoV-2 have the same cell entry mechanism, the pathogenesis of both viruses could be the same, or at least very similar (12) . ACE2 is the common factor that binds to the superficial S glycoprotein on the envelope of the virus. It seems that this binding is sensed (essentially) by Toll-like receptor-7 (TLR-7), which is present in endosomes, and which then leads to the secretion of inflammatory cytokines (13, 14) . ACE2 is highly expressed in some organs, like lung epithelial cells, especially type II pneumocytes, and in cells of the heart, kidneys, gastrointestinal tract, liver, and bladder (15, 16) . Therefore these organs constitute the main target for the virus. Following entry of SARS-CoV-2 into the cell, the viral RNA genome is transferred from the envelope into the cytoplasm and the translation process begins. After replication of the RNA new viral particles are formed, by incorporating part of the host cell membrane in the new viral envelope. Although, SARS-CoV-2 buds from the infected cell, it does not lyse it directly (17) . Infected lung epithelial cells produce interleukin (IL)-8 which acts as a chemoattractant for neutrophils and T lymphocytes (18) . The innate immune response is J o u r n a l P r e -p r o o f 5 initially triggered by lung epithelial cells, alveolar macrophages and neutrophils. In the next stage, adaptive immune responses are triggered involving T and B lymphocytes to complete the complete immune response (19) . Virus particles containing single-stranded ssRNA, act as pathogen-associated molecular patterns (PAMPs), and provoke a strong innate immune response after recognition by Toll-like receptor 7 (TLR7), which is expressed on monocytemacrophages and dendritic cells (DC). TLR7 can activate several signaling pathways and transcription factors, such as Janus kinase transducers (JAK/STAT), nuclear factor κB (NF-κB), activator protein 1 (AP-1), interferon response factor 3 (IRF3), and IRF7. This signaling cascade leads to increased secretion of pro-inflammatory cytokines, like IL-1, IL-6, monocyte chemo attractant protein-1 (MCP-1), MIP-1A, tumor necrosis factor α (TNF-α) and ultimately interferon 1 (IFN1) (20) . Furthermore, neutrophils are rapidly recruited to sites of infection, where they kill viruses by an oxidative burst, defensin secretion, and neutrophil extracellular traps (NETs) (21) .

Along with these events, antigen presentation subsequently stimulates the body's specific adaptive immunity (both humoral and cellular immunity) which culminates in approximately 7-14 days after infection. Following the representation of antigens by APCs to the CD4+ and CD8+

T-cells, pro-inflammatory cytokines are produced via the NF-κB signaling pathway. Activated B cells secrete virus-specific antibodies, while antigen-specific T cytotoxic cells kill virus-infected cells (17, 22) . Additionally, Th17 cells, neutrophils, and granulocytes secrete IL-17, which in turn stimulates production of IL-1, IL-6, IL-8, MCP-1, Gro-a, G-CSF, GM-CSF, TNF-α, and PGE2. All these mediators can increase the recruitment of neutrophils, monocytes, and other immune cells. Besides, it has been reported that IL-17 expression is correlated with several inflammatory J o u r n a l P r e -p r o o f 6 respiratory diseases (23) . All these immune signaling pathways are designed to create an inflammatory environment with the goal of eradicating SARS-CoV-2.

The pathology of SARS-CoV-2 is not yet completely understood; most of our knowledge has been based on research into SARS-CoV and MERS, which previously caused epidemics of acute respiratory syndromes. In this short duration of the present pandemic, studies have shown that SARS-CoV-2 has several defense mechanisms, which makes its eradication more difficult. The (7, 20, 24, 25) . Another important observation is the strong correlation between inflammatory markers, including ESR, CRP and IL-6, and the relevant subset of lymphocytes (26) . Overall, general lymphopenia is seen in COVID-19 patients, especially in severe cases (27, 28) .

Similar to all infectious diseases, the immune system plays an essential role in virus suppression. Therefore, it can be assumed that suppression of the immune defense system will make the situation worse, but it is not as simple as it sounds (29) . There has not yet been enough scientific evidence to generally employ immunosuppressive drugs in autoimmune diseases like rheumatoid arthritis (RA) (30, 31) . On the other hand, the hyper-inflammatory and cytokine release syndrome (CRS) typical of COVID-19 causes tissue damage to the lung epithelium and ARDS (32); therefore, immunosuppressive drugs may be useful as there is some evidence that an anti-IL-6 approach is effective in critically ill patients in the ICU (33) . Another high-risk group for COVID-19 is cancer patients, who are administered cytotoxic drugs. Although their immune function may be at an acceptable level, some cytotoxic drugs such as 6-MP used in chemotherapy, have shown destructive effects on virus replication in vitro (31) . On the other hand, the high number of critically ill patients and increased mortality in patients with underlying diseases (such as hypertension and diabetes) has been proven (34) . Diabetes mellitus type II can include a hyperinflammatory state with a low-grade inflammatory activity that causes long-term immune system stimulation (35) , along with adipose tissue side effects J o u r n a l P r e -p r o o f 8 on the immune system, which ultimately drives an immune imbalance (36) . Also, due to the overexpression of ACE2 in islet cells of the pancreas, SARS-CoV-2 may be a diabetogenic virus that causes severe instability in the blood glucose levels of diabetes patients, which worsens the inflammatory imbalance (37) . As a consequence, the condition of diabetic patients can be worsened after COVID-19 infection, as evidenced by the higher levels of multiple enzymes and inflammatory cytokines compared to nondiabetic individuals with COVID-19 pneumonia (38).

CD147, also known as Basigin or extracellular matrix metalloproteinase inducer (EMMPRIN), is also recognized as a red blood cell (RBC) receptor for the parasite that causes malaria in humans, and is a transmembrane protein of the immunoglobulin family. Its expression is induced in several conditions such as asthma, cancer stem cells, high glucose concentration in monocytes, and inflammatory processes (39) . Wang et al. recently demonstrated that the SARS-CoV-2 SP also binds to CD147 (40); so, the immune system itself could be an entryway for SARS-CoV-2. (27, 46) . Although the typical MAS/sHLH pathology that occurs in immunocompetent patients, may also be seen in COVID-19, but the differentiation between these two patterns is difficult.

Although COVID-19 has numerous manifestations, lung injury and severe respiratory failure (SRF) are more common than others. The cornerstone of this condition is MAS/sHLH or immune dysregulation. Alveolar macrophages secret IL-6 that cause overproduction of pro-inflammatory cytokines by monocytes, and dysregulation of lymphocytes, characterized by CD4 lymphopenia and subsequently B cell lymphopenia. In parallel, the absolute natural killer (NK) cell count is depleted, probably as a result of the rapidly multiplying virus. Moreover, IL-6 decreases the expression of HLA-DR on the membrane and production of IFN-Ƴ by CD4 cells (4) . In conclusion, it seems that innate immunity, characterized by neutrophils and proinflammatory cytokines in the format of the cytokine storm, is trying to limit the infection and overcome the virus; however, it leads to an excessive inflammatory response rather than harming the virus. This causes lung injury with tissue damage and life-threatening edema, enriched with mucins and fibrin, that unfortunately causes SRF and death in severely affected patients (22) .

It seems that lymphopenia, hyper-inflammatory state, and cytokines all play a role in the pathology of COVID-19; hence the hypothesis was proposed that immunomodulatory drugs may be beneficial to reverse the condition and treat the disease (47) . Seroconversion and antibody production occurs by the first two weeks after infection (48) . Like other infections, specific IgM is the first defense to appear, and disappears after a short time, but specific IgG remains a long-term defense against the virus. Therefore, neutralizing IgGs play a major role in the patient recovery and control of infection. IgGs reach their peak in the serum during the convalescent phase, and tend to wane after recovery, but memory B cells could still survive to offer long-term protection (22, 49) .

There is a global effort to find an effective treatment for COVID-19. Although the benefits of some available drugs have been proven, they are not yet a certain specific cure for the disease, and controversies remain (50) . According to previous experience with other coronavirus family members, convalescent plasma therapy has been tested on some critically ill patients, with 

The worldwide economy, culture, transport, sport, interpersonal relationships, education and each individual's lifestyle have been influenced by the COVID-19 pandemic (57) . However, the lethality of this virus is much lower than found in previous pandemics. What makes COVID-19 so significant and dangerous, is the rapid acceleration of the virus transmission. Despite all efforts to control and treat this disease, public quarantine and lockdown measures cannot be implemented for ever, and all tested treatment methods have not been sufficiently effective.

Therefore, along with trying to find more effective specific drugs, the effort to find a vaccine should be redoubled in order to gain herd immunity and allow the world to return to normal life and resume its routine. Because the process of vaccine preparation and testing is J o u r n a l P r e -p r o o f 13 complicated and lengthy, validating and marketing vaccines can be tedious, but given the body of work by various research groups, there is a clear prospect of achieving this goal sooner rather than later (20, 58, 59) .

The COVID-19 pandemic is an ongoing issue that affects the lives of most people around the world. Most countries are now semi-closed, strict travel regulations have been enacted, international relations have been affected, and humans are experiencing an unprecedented regime, which has changed ordinary life (60) . Therefore, it is of the utmost importance to understand the pathophysiology of disease and how the immune response to the pathogen affects the disease. Although the immune system plays an important role in fighting COVID-19, paradoxically it could also be harmful. Most critically ill patients in ICU, that develop ARDS, have high levels of inflammatory cytokines in their circulation, known as CRS. Considering all the reported data from observations and measurements, it seems that when the immune system is severely damaged and becomes inefficient by lymphopenia and Tex, it tries to compensate by triggering the CRS, which could potentially lead to complications like ARDS and multi-organ failure. It is necessary to find efficient drugs and vaccines to return to the normal situation and reduce the mortality rate.

J o u r n a l P r e -p r o o f

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

COVID-19: Developing from an outbreak to a pandemic

Cutaneous manifestations of the Coronavirus Disease 2019 (COVID-19): a brief review

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review

Central nervous system involvement in COVID-19. Archives of Medical Research

Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives

ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia

COVID-19 affects healthy pediatricians more than pediatric patients

A human homolog of angiotensinconverting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Immune-epidemiological parameters of the novel coronavirus -a perspective

A Current Emerging Respiratory Infection: Epidemiological and Clinical Characteristics, Diagnosis and Treatments of COVID-19 The Lancet

A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19

Molecular immune pathogenesis and diagnosis of COVID-19

Vascular pharmacology of acute lung injury and acute respiratory distress syndrome

Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS. Reviews in Medical Virology

Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic

Targeting potential drivers of COVID-19: Neutrophil extracellular traps

Coronavirus infections and immune responses

Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?

CoViD-19 Immunopathology & Immunotherapy

Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia

Lymphopenia in COVID-19: therapeutic opportunities Cell Biol Int

Benign COVID-19 in an immunocompromised cancer patientthe case of a married couple

Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. The Lancet Rheumatology

Associations between immunesuppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence

On the alert for cytokine storm: Immunopathology in COVID-19. Arthritis & Rheumatology

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis

Cells of innate and adaptive immunity in type 2 diabetes and obesity

Tissue resident macrophages: Key players in the pathogenesis of type 2 diabetes and its complications

Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes

Diabetes is a risk factor for the progression and prognosis of COVID-19

CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement

SARS-CoV-2 invades host cells via a novel route: CD147-spike protein

Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids

Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup

Potent human neutralizing antibodies elicited by SARS-CoV-2 infection bioRxiv

Current Drugs with Potential for Treatment of COVID-19: A Literature Review

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?

Convalescent Plasma to Treat COVID-19

Convalescent plasma: A possible treatment of COVID-19 in India

Treatment with convalescent plasma for COVID-19 patients in Wuhan

A human monoclonal antibody blocking SARS-CoV-2 infection

Borderless collaboration is needed for COVID-19; a disease that knows no borders

Can an effective SARS-CoV-2 vaccine be developed for the older population?

Progress and Prospects on Vaccine Development against SARS-CoV-2. Vaccines

All together to Fight Novel Coronavirus Disease (COVID-19) The American Journal of Tropical Medicine and Hygiene